1. Generics Bulletin
  2. >>Products

IGBA Builds On Partnership With WHO

Collaborating On Widening Access And Promoting Uptake

 
• By Dave Wallace

In the first in a series of exclusive interviews, IGBA chair Hanan Sboul talks about the international off-patent industry association’s collaboration with the WHO and how it is expected to develop in future.

WHO
The IGBA is strengthening its relationship with the WHO • Source: Shutterstock

When Hanan Sboul, secretary general of the Jordanian Association of Pharmaceutical Manufacturers, was appointed to take over as chair of the International Generic and Biosimilar Medicines Association for 2020, she was clear on the global off-patent industry body’s priorities.

Replacing Jim Keon – president of the Canadian Generic Pharmaceutical Association and Biosimilars Canada – who chaired the IGBA in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

More from Products

Generic Drug Office’s Policy Staff Returning To US FDA

 
• By Derrick Gingery

The group had been laid off as part of the 1 April reduction-in-force, which lead to missed guidance publication deadlines.

Stelara Biosimilar Sees Stada’s Specialty Sales Start Strong In Q1

 
• By Dave Wallace

Stada’s Specialty division was boosted by the firm’s launch last year of a European Stelara biosimilar, even as generics growth remained muted in Q1.

Formycon Snatches Brazilian Approval For Lucentis Biosimilar

 
• By Urtė Fultinavičiūtė

Formycon is preparing to start a new era – entering Latin America with its ranibizumab biosimilar, which is expected to be a “good contributor” to the firm’s finances.